Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SPDR Series Trust SPDR S&P Biotech ETF (NY:XBI)

79.02 +1.44 (+1.86%)
Official Closing Price Updated: 8:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SPDR Series Trust SPDR S&P Biotech ETF

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Can Biotech Stocks Continue Rallying In This Bear Market?
Via Talk Markets
This Beaten-Down ETF Is Still a Screaming Bear-Market Buy
Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund. 
Via The Motley Fool
Steady As She Goes With Healthcare Stocks
Favorable seasonality lies ahead for Q4 with a caveat of Q3 earnings reports. 
Via Talk Markets
My 3 Biggest Stock Market Predictions for October
Now's not the best time to bet the farm on anything other than more uncertainty coming up. 
Via The Motley Fool
Choppy Days Lie Ahead So Why Fight The Fed?
We are in a bear market with choppy days over the next few months. 
Via Talk Markets
Stocks May Be Nearing A Breaking Point
We are seeing high yield spreads widen, and looking at the ratio of the SHY to HYG; it is clear that we surpassed the June highs. 
Via Talk Markets
AskSlim Market Week - Friday, July 22
Technical and cycle analysis, and market commentary. 
Via Talk Markets
UUP ETF – Trade Setup Of The Week
UUP has been trending higher while the rest of the stock and bond market has been falling. 
Via Talk Markets
Can Healthcare Stocks Continue To Outperform?
Large-cap healthcare and biotech stocks have been resilient amidst the market turmoil caused by rising rates and the global geopolitical crisis. 
Via Talk Markets
Rare Economic/Technical Signal Has Only Flashed 9 Times In Last 54 Years
A rare stock market signal combining technical and economic data was recently flashed. What can we learn from history regarding stock market/recession probabilities? 
Via Talk Markets
3 Biotech Stocks to Buy Now for Extraordinary Gains
These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market. 
Via InvestorPlace
Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year
The biotech run off a June bottom is great — until you realize you could've netted more. 
Via Investor's Business Daily
The Three Best Anti-Aging Stocks to Buy in September
These three anti-aging stocks could see recovery ahead. ATHX, LCTX, and UBX can make great long-term investments 
Via InvestorPlace
Biotech Stocks Stand to Benefit as Biden Announces Support for Industry
President Biden has announced a new initiative to help U.S. biotech producers grow. Here's what this news means for biotech stocks. 
Via InvestorPlace
5 Monster Stock Market Predictions For The Week Of Sept. 12
This week will be interesting, with inflation data Tuesday and Wednesday. There will be a lot of Treasury auctions this week, which will move yields and stocks. The one wrinkle is that the VIX options... 
Via Talk Markets
Stocks Drop On August 6 As Financial Conditions Tightening More
Today’s battle for the S&P 500 was between 3,900 and 3,920. Right now, the index is just consolidating and is likely to drop to around 3,820 over the near term to fill the gap at that level. 
Via Talk Markets
REITs And Utilities Show Glimmer As The S&P Wilts
The S&P 500 failed to close below last Thursday's low as Utilities and REITs were bid. 
Via Talk Markets
Healthcare Sector Still Looks Good But Lacks Momentum
The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord... 
Via Talk Markets
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
Whither Small Caps After Fed’s Tough Talk?
For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and... 
Via Talk Markets
3 Investing Themes For The Next 3 Years
With all of the noise about Jackson Hole tomorrow and whether they will be hawkish, dovish, pivot or not, we wanted to take a step back and think about broad themes we are/will be pursuing over the... 
Via Talk Markets
“Wrong Side Of The Wave” Stock Market (And Sentiment Results)
Spreads peaked at 6% in early July and have now rolled over to 4.24% (176 bps) in the past 5 weeks alone. This looks more like a small “aftershock” than a new earthquake. 
Via Talk Markets
Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation?
The SPDR S&P Biotech ETF remains our key indicator for small cap biotechs. It is up 14.55% over one month at $93.78 but is still down 16% YTD. The Russell 2000 is up 16.5% over one month mirroring... 
Via Talk Markets
Exploding Interest Rates May Finally Suck Stocks Lower
Stocks moved lower today, despite moving sharply higher to start. 
Via Talk Markets
Small Cap Biotechs Perk Up On Dealmaking
With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology. 
Via Talk Markets
Stocks Stall On August 1, As Stagflation Appears To Have Finally Arrived
Today financial conditions tightened some, with the IEF/LQD ratio moving up by 45 bps. 
Via Talk Markets
Bullish Expanding Falling Wedge
I’ve been mentioning lately that I thought that many areas in the PM complex could be building out a potential bullish expanding falling wedge. This is a bullish pattern that few if any chartists... 
Via Talk Markets
The 3 Best Market Sectors for the Second Half of 2022
Compelling themes will drive a recovery in some sectors over the second half of 2022. The following are the best market sectors to buy into. 
Via InvestorPlace
Chris Stapleton “Starting Over” Stock Market (And Sentiment Results)
The “hard roads” are stepping in at times like these when others are selling in the hole. We saw it with China stocks bottoming in March. We saw it with Biotech bottoming in May. We may now be seeing... 
Via Talk Markets
Broad Market Rallies Despite Currency Headwinds
HealthCare and Biotech shares have been strong over the past 30 days as investors have sought trades away from macro and earnings concerns. In times of volatility portfolio strategists may re-balance... 
Via Talk Markets
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.